The Pharmacological Treatment and Management of Obesity

References

• . World Health Organization. Obesity and overweight fact sheet. 2006. http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed July 26, 2010
   Google Scholar
• . Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–241
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Global strategy on diet, physical activity, and health—2003. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/. Accessed July 26, 2010
   Google Scholar
• . Getting a handle on obesity. Lancet. 2002;359(9322):1955
   Google Scholar
• . Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583–2589
   PubMed Web of Science ®Google Scholar
• . Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol. 2010;6(8):444–453
   Google Scholar
• . James WP. The fundamental drivers of the obesity epidemic. Obes Rev. 2008;9( suppl 1):6–13
   PubMedGoogle Scholar
• . Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132(6):2226–2238
   PubMed Web of Science ®Google Scholar
• . Colman RJ, Anderson RM, Johnson SC, . Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325(5937):201–204
   PubMed Web of Science ®Google Scholar
• . Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res. 2001;9(suppl 1):1S–40S
   PubMedGoogle Scholar
• . Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43–53
   PubMed Web of Science ®Google Scholar
• . Gardner CD, Kiazand A, Alhassan S, . Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA. 2007;297(9):969–977
   PubMed Web of Science ®Google Scholar
• . Alhassan S, Kim S, Bersamin A, King AC, Gardner CD. Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond). 2008;32(6):985–991
   Google Scholar
• . Sacks FM, Bray GA, Carey VJ, . Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859–873
   PubMed Web of Science ®Google Scholar
• . Williamson DF, Madans J, Anda RF, Kleinman JC, Kahn HS, Byers T. Recreational physical activity and ten-year weight change in a US national cohort. Int J Obes Relat Metab Disord. 1993;17(5):279–286
   PubMed Web of Science ®Google Scholar
• . Katzmarzyk PT, Church TS, Craig CL, Bouchard C. Sitting time and mortality from all causes, cardiovascular disease, and cancer. Med Sci Sports Exerc. 2009;41(5):998–1005
   PubMed Web of Science ®Google Scholar
• . Slentz CA, Duscha BD, Johnson JL, . Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE—a randomized controlled study. Arch Intern Med. 2004;164(1):31–39
   PubMed Web of Science ®Google Scholar
• . Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord. 1997;21(10):941–947
   Web of Science ®Google Scholar
• . Ross R, Dagnone D, Jones PJ, . Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000;133(2):92–103
   PubMed Web of Science ®Google Scholar
• . Jakicic JM, Marcus BH, Lang W, Janney C. Effect of exercise on 24-month weight loss maintenance in overweight women. Arch Intern Med. 2008;168(14):1550–1560
   PubMed Web of Science ®Google Scholar
• . Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK; American College of Sports Medicine. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009;41(2):459–471
   PubMed Web of Science ®Google Scholar
• . National Institutes of Health. National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH publication 00-4084, October 2000. Washington, DC: NHLBI; 2000
   Google Scholar
• . Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066–1068
   PubMedGoogle Scholar
• . Svetkey LP, Stevens VJ, Brantley PJ, . Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008;299(10):1139–1148
   PubMed Web of Science ®Google Scholar
• . Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194–1199
   PubMed Web of Science ®Google Scholar
• . Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004(3):CD004094
   Google Scholar
• . Kaya A, Aydin N, Topsever P, . Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother. 2004;58(10):582–587
   Google Scholar
• . Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142(7):525–531
   PubMed Web of Science ®Google Scholar
• . Zhi J, Melia AT, Guerciolini R, . Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82–85
   PubMed Web of Science ®Google Scholar
• . Li Z, Maglione M, Tu W, . Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–546
   PubMed Web of Science ®Google Scholar
• . Hollander PA, Elbein SC, Hirsch IB, . Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288–1294
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Hauptman J, DiGirolamo M, . Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235–242
   PubMed Web of Science ®Google Scholar
• . Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132(6):2239–2252
   Google Scholar
• . Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1(5588):352–354
   PubMed Web of Science ®Google Scholar
• . Connolly HM, Crary JL, McGoon MD, . Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9): 581–588
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9): 574–579
   PubMed Web of Science ®Google Scholar
• . Knowler WC, Barrett-Connor E, Fowler SE, ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Henry RR, Poon TH, . Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 2006;22(6):483–491
   Google Scholar
• . Ratner RE, Maggs D, Nielsen LL, . Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8(4):419–428
   PubMed Web of Science ®Google Scholar
• . Bode BW, Testa MA, Magwire M, ; LEAD-3 Study Group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(7):604–612
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Whitehouse F, Kruger DF, Fineman M, . A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724–730
   PubMed Web of Science ®Google Scholar
• . Hollander PA, Levy P, Fineman MS, . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784–790
   PubMed Web of Science ®Google Scholar
• . Hollander P, Maggs DG, Ruggles JA, . Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12(4):661–668
   PubMedGoogle Scholar
• . Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289(14):1820–1825
   PubMed Web of Science ®Google Scholar
• . Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994;18(3):129–135
   PubMed Web of Science ®Google Scholar
• . Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10(7):633–641
   PubMedGoogle Scholar
• . Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008;32( suppl 7):S93–S97
   PubMed Web of Science ®Google Scholar
• . Sjostrom L, Lindroos AK, Peltonen M, ; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–2693
   PubMed Web of Science ®Google Scholar
• . Buchwald H, Estok R, Fahrbach K, . Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–256.e5
   PubMed Web of Science ®Google Scholar
• . Laferrere B, Heshka S, Wang K, . Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30(7):1709–1716
   PubMed Web of Science ®Google Scholar
• . Maggard MA, Shugarman LR, Suttorp M, . Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547–559
   PubMed Web of Science ®Google Scholar
• . Birkmeyer NJ, Dimick JB, Share D, . Hospital complication rates with bariatric surgery in Michigan. JAMA. 2010;304(4):435–442
   Web of Science ®Google Scholar
• . NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956–961
   PubMed Web of Science ®Google Scholar
• . McEwen LN, Coelho RB, Baumann LM, Bilik D, Nota-Kirby B, Herman WH. The cost, quality of life impact, and cost-utility of bariatric surgery in a managed care population. Obes Surg. 2010;20(7):919–928
   PubMed Web of Science ®Google Scholar
• . Thomsen WJ, Grottick AJ, Menzaghi F, . Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577–587
   PubMed Web of Science ®Google Scholar
• . Smith SR, Weissman NJ, Anderson CM, . Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256
   PubMed Web of Science ®Google Scholar
• . Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1117–1125
   PubMed Web of Science ®Google Scholar
• . Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8):1226–1229
   PubMed Web of Science ®Google Scholar
• . Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906–1913
   PubMed Web of Science ®Google Scholar
• . Addy C, Rothenberg P, Li S, . Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol. 2008;48(6):734–744
   Google Scholar
• . Batterham RL, Cohen MA, Ellis SM, . Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349(10): 941–948
   PubMed Web of Science ®Google Scholar
• . Considine RV, Sinha MK, Heiman ML, . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–295
   PubMed Web of Science ®Google Scholar
• . Farooqi IS, Jebb SA, Langmack G, . Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879–884
   PubMed Web of Science ®Google Scholar
• . Roth JD, Roland BL, Cole RL, . Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from non-clinical and clinical studies. Proc Natl Acad Sci U S A. 2008;105(20): 7257–7262
   PubMed Web of Science ®Google Scholar
• . Wynne K, Park AJ, Small CJ, . Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12):1729–1736
   PubMed Web of Science ®Google Scholar
• . Chaudhri OB, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity? Diabetes Care. 2008;31( suppl 2):S284–S289
   PubMed Web of Science ®Google Scholar
• . Batterham RL, Le Roux CW, Cohen MA, . Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88(8):3989–3992
   PubMed Web of Science ®Google Scholar
• . Lin S, Shi YC, Yulyaningsih E, . Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One. 2009;4(12):e8488
   PubMed Web of Science ®Google Scholar
• . Day JW, Ottaway N, Patterson JT, . A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757
   PubMed Web of Science ®Google Scholar
• . Inui A, Asakawa A, Bowers CY, . Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 2004;18(3):439–456
   PubMed Web of Science ®Google Scholar
• . Erdmann J, Lippl F, Wagenpfeil S, Schusdziarra V. Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes. 2005;54(5):1371–1378
   PubMed Web of Science ®Google Scholar
• . Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res. 2000;8(5): 399–402
   Google Scholar
• . Astrup A, Buemann B, Flint A, Raben A. Low-fat diets and energy balance: how does the evidence stand in 2002? Proc Nutr Soc. 2002;61(2):299–309
   Google Scholar
• . Nordmann AJ, Nordmann A, Briel M, . Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(3):285–293
   PubMed Web of Science ®Google Scholar
• . Acheson KJ. Carbohydrate for weight and metabolic control: where do we stand? Nutrition. 2010;26(2):141–145
   Google Scholar
• . Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008;337:a1344
   PubMed Web of Science ®Google Scholar
• . Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring). 2006;14(8): 1283–1293
   PubMed Web of Science ®Google Scholar